Eli LillyLLY
LLY
About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Employees: 43,000
0
Funds holding %
of 6,814 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
114% more first-time investments, than exits
New positions opened: 244 | Existing positions closed: 114
12% more repeat investments, than reductions
Existing positions increased: 1,530 | Existing positions reduced: 1,370
2% more funds holding
Funds holding: 3,498 [Q2] → 3,583 (+85) [Q3]
0% more capital invested
Capital invested by funds: $736B [Q2] → $736B (+$29.6M) [Q3]
1.74% less ownership
Funds ownership: 85.62% [Q2] → 83.88% (-1.74%) [Q3]
12% less call options, than puts
Call options by funds: $9.4B | Put options by funds: $10.7B
15% less funds holding in top 10
Funds holding in top 10: 543 [Q2] → 461 (-82) [Q3]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$975
24%
upside
Avg. target
$1,062
35%
upside
High target
$1,250
59%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Tim Anderson 33% 1-year accuracy 2 / 6 met price target | 26%upside $997 | Buy Reinstated | 10 Dec 2024 |
Wolfe Research Alexandria Hammond 33% 1-year accuracy 3 / 9 met price target | 27%upside $1,000 | Outperform Initiated | 15 Nov 2024 |
Deutsche Bank James Shin 0% 1-year accuracy 0 / 4 met price target | 29%upside $1,015 | Buy Maintained | 4 Nov 2024 |
Barclays Carter Gould 34% 1-year accuracy 13 / 38 met price target | 24%upside $975 | Overweight Maintained | 31 Oct 2024 |
B of A Securities Geoff Meacham 41% 1-year accuracy 11 / 27 met price target | 40%upside $1,100 | Buy Maintained | 31 Oct 2024 |
Financial journalist opinion
Based on 101 articles about LLY published over the past 30 days
Neutral
PRNewsWire
2 hours ago
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3K α inhibitor currently in a Phase 1/2 clinical trial STX-478 could potentially address 30-40% of people with hormone-positive breast cancer, building on Lilly's advancements against this disease INDIANAPOLIS and BOSTON, Mass. , Jan. 13, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive agreement for Lilly to acquire Scorpion's PI3Kα inhibitor program STX-478.
Negative
Reuters
6 hours ago
Lilly sues two medical spas over copycat weight-loss drugs
Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.
Neutral
Seeking Alpha
2 days ago
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Positive
Reuters
2 days ago
Andreessen Horowitz, Eli Lilly to launch $500 million venture fund
Venture capital firm Andreessen Horowitz said on Friday it was working with Eli Lilly to launch a $500 million venture fund that will be fully funded by the U.S. drugmaker.
Positive
CNBC
3 days ago
High-cost weight loss drugs are sending employers to nutrition counseling in a boost for startups
Employers are increasingly requiring workers on GLP-1 medications to enroll in nutrition and lifestyle coaching programs. Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss management program.
Neutral
Business Wire
3 days ago
Andreessen Horowitz Partners with Lilly to Launch First-of-Its-Kind Biotech Ecosystem Venture Fund
MENLO PARK, Calif.--(BUSINESS WIRE)--Andreessen Horowitz (a16z) Bio + Health today announced a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health, in partnership with Eli Lilly and Company (“Lilly”). The Biotech Ecosystem Venture Fund (“Fund”) seeks to drive transformative progress in healthcare by investing in therapeutic platforms and cutting-edge technology companies that can bring new medicines and disease treatments to improve patients' lives. M.
Positive
Zacks Investment Research
3 days ago
Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?
Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.
Positive
Investopedia
3 days ago
Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea
Popular Eli Lilly (LLY) weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and Drug Administration (FDA) approval last month.
Positive
Market Watch
4 days ago
Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment costs about $1,000 a month without insurance.
Positive
Zacks Investment Research
4 days ago
LLY Falls Around 14% in 3 Months: How to Play the Stock
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Charts implemented using Lightweight Charts™